Hemoglobin-based oxygen carrier: What we have learned and where we are heading?

Protein & cell

DOI 10.1093/procel/pwag019 PMID 41875375 Source

Abstract

A portable, universal, easy-to-preserve alternative of human red blood cells (RBC) has been pursued for decades in order to expand the limited blood supply, with Hemoglobin-Based Oxygen Carrier (HBOC) being one of the most promising techniques. Through two generations of development, various HBOC products were designed to emulate the natural RBCs with better biochemical and physical properties, but their over-ambitious product positioning and irrational clinical designs impeded their final approval. Now in its third generation, HBOC is finally poised for its commercialization with clearer views on a proper indication for use. Here, we review the development of HBOC, update the current pipeline and outline key lessons we have learned through past failures. We also specify its use scenario and propose future development to provide a more complete picture of the past, present and future of HBOC.

Topics

hemoglobin-based oxygen carrier HBOC development review, red blood cell substitute artificial blood transfusion, HBOC third generation commercialization clinical trials, hemoglobin oxygen carrier product design biochemical properties, blood substitute hemorrhage treatment alternative, HBOC clinical trial failures lessons learned, portable universal blood alternative organ preservation, artificial red blood cells hemoglobin engineering pipeline, blood supply expansion hemoglobin-based products, HBOC product indication clinical design review
PMID 41875375 41875375 DOI 10.1093/procel/pwag019 10.1093/procel/pwag019

Cite this article

Fehring, R. J. (2012). *Current Medical Research*. https://doi.org/10.1179/002436312803571537